Geneos Wealth Management’s ImmuCell ICCC Stock Holding History

Geneos Wealth Management’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-244	Closed	-$1.22K	–	2119
2023 Q2	$1.22K	Hold	244	–	–	﹤0.01%	2003
2023 Q1	$1.25K	Hold	244	–	–	﹤0.01%	1968
2022 Q4	$1.49K	Hold	244	–	–	﹤0.01%	1916
2022 Q3	$1K	Hold	244	–	–	﹤0.01%	1933
2022 Q2	$2K	Buy	+244	New	+$2.12K	﹤0.01%	2392

Other funds holding ICCC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SRC

Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OMC

Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

Geneos Wealth Management's ICCC Position: Q3 2023 in Review

Geneos Wealth Management sold out of ImmuCell (ICCC) in Q3 2023, closing a stake of 244 shares — an estimated $1.22K sold.

Geneos Wealth Management first reported a position in ICCC in Q2 2022 and held it in 5 quarters. The position peaked at $2K in Q2 2022. 30 funds tracked by Wall St. Rank hold ICCC as of Q3 2023.

Geneos Wealth Management reported no remaining ImmuCell position as of Q3 2023 after selling out during the quarter.
Geneos Wealth Management sold 244 ImmuCell shares in Q3 2023, an estimated $1.22K.
Geneos Wealth Management first reported a position in ImmuCell in Q2 2022 and held it in 5 quarters.
Geneos Wealth Management's ImmuCell position peaked at $2K in Q2 2022.
30 funds tracked by Wall St. Rank held ImmuCell as of Q3 2023.

Based on Geneos Wealth Management's 13F filing for Q3 2023, filed 11 Oct 2023.